Form 8-K - Current report:
SEC Accession No. 0001650664-25-000077
Filing Date
2025-05-13
Accepted
2025-05-13 07:04:55
Documents
16
Period of Report
2025-05-13
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K edit-20250513.htm   iXBRL 8-K 29160
2 EX-99.1 editasmedicineasgctundiscl.htm EX-99.1 26141
7 image_0.jpg GRAPHIC 10702
  Complete submission text file 0001650664-25-000077.txt   210894

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT edit-20250513.xsd EX-101.SCH 2129
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT edit-20250513_def.xml EX-101.DEF 2931
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT edit-20250513_lab.xml EX-101.LAB 23733
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT edit-20250513_pre.xml EX-101.PRE 14223
18 EXTRACTED XBRL INSTANCE DOCUMENT edit-20250513_htm.xml XML 2714
Mailing Address 11 HURLEY ST. CAMBRIDGE MA 02141
Business Address 11 HURLEY ST. CAMBRIDGE MA 02141 617-401-9000
Editas Medicine, Inc. (Filer) CIK: 0001650664 (see all company filings)

EIN.: 464097528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37687 | Film No.: 25937092
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)